A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia

Eur J Cancer. 2019 Mar:110:49-52. doi: 10.1016/j.ejca.2019.01.011. Epub 2019 Feb 8.

Authors

Mathilde Berger¹, Mona Amini-Adlé¹, Laura Crumbach¹, Etienne Paubelle², Stéphane Dalle³

Affiliations

¹ Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Dermatologie, Pierre-Bénite, France.
² Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'hématologie, Pierre-Bénite, France. Electronic address: etienne.paubelle@chu-lyon.fr.
³ Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Dermatologie, Pierre-Bénite, France. Electronic address: stephane.dalle@chu-lyon.fr.

PMID: 30739840
DOI: 10.1016/j.ejca.2019.01.011

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary*
Female
Humans
Melanoma / secondary*
Melanoma / therapy
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
Red-Cell Aplasia, Pure / chemically induced*
Red-Cell Aplasia, Pure / immunology
Skin Neoplasms

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab